Tudor Investment Corp ET AL Has $7.83 Million Stake in GeneDx Holdings Corp. (NASDAQ:WGS)

Tudor Investment Corp ET AL raised its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 67.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 101,810 shares of the company's stock after purchasing an additional 41,084 shares during the period. Tudor Investment Corp ET AL owned approximately 0.37% of GeneDx worth $7,825,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of WGS. MCF Advisors LLC raised its holdings in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after acquiring an additional 182 shares during the period. Sterling Capital Management LLC raised its stake in shares of GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after purchasing an additional 316 shares during the period. Global Retirement Partners LLC bought a new stake in shares of GeneDx in the fourth quarter valued at about $28,000. Quarry LP acquired a new position in shares of GeneDx during the fourth quarter worth about $78,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of GeneDx during the fourth quarter worth about $200,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on WGS. Wells Fargo & Company reduced their price objective on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a research note on Thursday. TD Securities decreased their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday. The Goldman Sachs Group boosted their price target on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Finally, TD Cowen increased their price objective on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $78.14.

Insider Buying and Selling at GeneDx

In related news, CEO Katherine Stueland sold 10,559 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $96.71, for a total transaction of $1,021,160.89. Following the transaction, the chief executive officer now directly owns 14,865 shares of the company's stock, valued at approximately $1,437,594.15. This trade represents a 41.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Feeley sold 388 shares of the business's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total transaction of $43,878.92. Following the completion of the sale, the chief financial officer now directly owns 3,337 shares of the company's stock, valued at $377,381.33. This represents a 10.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 139,390 shares of company stock valued at $13,043,288 in the last three months. 27.30% of the stock is currently owned by company insiders.

GeneDx Stock Performance

Shares of NASDAQ WGS traded down $2.37 during midday trading on Monday, hitting $64.86. 529,593 shares of the company's stock were exchanged, compared to its average volume of 717,456. GeneDx Holdings Corp. has a 12 month low of $18.80 and a 12 month high of $117.75. The company's 50 day moving average price is $94.30 and its 200 day moving average price is $82.91. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.82 billion, a PE ratio of -33.26 and a beta of 1.93.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. The firm had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.